GlassScriptPhysician profile
Sara Turner Cooper
NPI 1457029902
$8,688.83
in general payments reported to CMS, 2019-2025
39 companies · $2,713 in 2025
The $2,713 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $226 · 2022: $1,095 · 2023: $1,791 · 2024: $2,863 · 2025: $2,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,560 · Travel and Lodging: $787 · Education: $20.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,560.44 |
| Travel and Lodging | $786.88 |
| Education | $20.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $1,257.00 | 2024 | |
| Lilly USA, LLC | $947.28 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Ascensia Diabetes Care US INC. | $873.46 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $727.19 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amgen INC. | $561.83 | 2022-2025 | Evenity, Prolia, Repatha |
| Tandem Diabetes Care, INC. | $487.40 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $380.80 | 2023-2025 | Afrezza, V-Go |
| Bayer Healthcare Pharmaceuticals INC. | $361.48 | 2021-2025 | |
| Novo Nordisk INC | $354.85 | 2022-2025 | Ozempic, Rybelsus, Saxenda |
| Corcept Therapeutics | $268.56 | 2023-2025 | Korlym |
| Beta Bionics, INC. | $256.63 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Radius Health, INC. | $248.57 | 2023-2025 | |
| Dexcom, INC. | $214.41 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.48 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Insulet Corporation | $157.56 | 2023-2025 | Omnipod |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $152.08 | 2025 | Freestyle Libre 3 |
| Cequr Corporation | $126.59 | 2024-2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $114.48 | 2021-2024 | |
| Glaxosmithkline, LLC. | $110.75 | 2021-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $110.12 | 2023-2024 | |
| Ascendis Pharma Endocrinology INC | $105.63 | 2025 | Yorvipath |
| Abbvie INC. | $100.96 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $92.76 | 2022-2025 | Farxiga |
| Kyowa Kirin, INC. | $88.08 | 2023-2025 | |
| Averitas Pharma INC. | $85.99 | 2024 | Qutenza |
| Biohaven Pharmaceuticals, INC. | $58.38 | 2021 | |
| Recordati_rare_diseases_inc. | $56.11 | 2024-2025 | Isturisa, Signifor Lar |
| Nevro Corp. | $33.98 | 2022-2023 | Senza |
| Bigfoot Biomedical INC | $29.93 | 2022 | |
| Ibsa Pharma INC. | $24.98 | 2025 | Flector, Tirosint, Licart |
| Medtronic, INC. | $19.08 | 2024 | Minimed 780g |
| Tolmar, INC. | $18.19 | 2025 | Jatenzo |
| Azurity Pharmaceuticals, INC. | $17.51 | 2025 | Azmiro |
| Esperion Therapeutics, INC. | $16.21 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $15.65 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $14.83 | 2021 | |
| Almatica Pharma LLC | $14.40 | 2025 | Teriparatide |
| Therapeuticsmd, INC. | $12.51 | 2021 | |
| Seqirus USA INC | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Turner Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.